Skip to main content

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Active, not recruiting · Phase 3 · NCT05566795

Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

At a glance

Research payments reported, 2025
$1.0M
U.S. investigators named
28
Sites paid
26
Planned or actual enrollment
418

About the trial

Sponsor
Day One Biopharmaceuticals, Inc. (with SIOPe Brain Tumor Group LOGGIC Consortium)
Tested
Tovorafenib (drug), Chemotherapeutic Agent (drug)
Dates
Started 2023-02-27; completion 2031-06
Results posted
Not yet

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.

From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Day One Biopharmaceuticals reported $1.0M in research payments for this study in 2025 (195 payments).

Products named: Ojemda

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.